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Summary 
Nuclear factor of activated T  cells-family proteins (NFAT1/NFATp, NFATc, NFAT3,  and 
NFAT4/NFATx/NFATc3) play a key role in the transcription of cytokine genes and other 
genes during the immune  response.  We have defined the mechanisms  of transactivation by 
NFAT1. NFAT1 possesses two transactivation domains whose sequences are not conserved in 
the other NFAT-family proteins, and a conserved DNA-binding domain that mediates the re- 
cruitment of cooperating nuclear transcription factors even when it is expressed in the absence 
of other regions of the protein.  The activity of the  NH2-terminal transactivation domain is 
modulated by an adjacent regulatory region that contains several conserved sequence motifs 
represented only in  the  NFAT  family.  Our  results  emphasize  the  multiple  levels at  which 
NFAT-dependent transactivation is regulated, and predict significant differences in the archi- 
tecture of cooperative transcription complexes containing different NFAT-family proteins. 
T 
he nuclear factor of activated T  cells (NFAT) 1 is a cal- 
cium-regulated transcription factor that is a major tar- 
get for the immunosuppressive drugs cyclosporin A  (CsA) 
and FK506 (1-3). The DNA-binding specificity of NFAT 
is  conferred by a  novel family of transcription factors,  of 
which four members (NFAT1/NFATp, NFATc, NFAT3, 
and  NFATx/NFAT4/NFATc3,  each  containing  several 
isoforms) have so far been described (4-9). NFAT1 protein 
is expressed in several classes of  immune system cells (10-12), 
consistent with the detection of  nuclear NFAT DNA-bind- 
ing activity in activated T, B, mast, and NK cells (13-19). 
The distribution of  the other NFAT-family proteins has not 
yet been assessed at the protein level; however the mR.NAs 
encoding these proteins differ in their cell and tissue distri- 
butions and their representation in resting versus activated 
cells (5-7), suggesting that each protein may subserve a dif- 
ferent function. NFATc mlLNA is expressed at high levels 
in skeletal muscle and in activated lymphoid cells, NFATx/ 
NFAT4 mP,.NA is predominantly expressed in the thymus, 
and NFAT3 mR.NA is most strongly expressed outside the 
immune system (5-7). 
An  important component of transactivation by NFAT- 
family proteins is their cooperation in the nucleus with Fos 
and Jun (20,  21). This cooperation is mediated by interac- 
1Abbreviations used in this paper: CAT, chloramphenicol  acetyltransferase; 
CsA, cyclosporin  A; DBD, DNA-binding domain; hGH, human growth 
hormone; NFAT, nuclear factor of activated T cells; NHP,., NFAT ho- 
mology  region; TAD, transactivation  domain. 
tion of the highly conserved DNA-binding domains (DBDs) 
of NFAT-family proteins with Fos-Jun and Jun-Jun dimers 
(6, 7, 22); the bZIP (basic region-leucine zipper) regions of 
Fos  and Jun  suffice for this  interaction  (21),  although  an 
acidic region of Fos has also been implicated (23).  Overex- 
pression of Fos- and Jun-family proteins in T  cells greatly 
augments transcription driven by tandem copies of the IL-2 
and IL-4 promoter NFAT sites in activated T  cells (20, 24- 
26).  It has also been suggested that NFAT-family proteins 
are able to act independently or cooperate with transcrip- 
tion factors of the GATA family (18, 27). We asked whether 
NFAT-family proteins contain intrinsic transactivation do- 
mains (TADs), or whether they function by recruiting other 
transcription factors. 
Here  we  define  the  mechanisms  of transactivation  by 
NFAT1. We show that NFAT1 contains two intrinsic TADs 
at its NH  2- and COOH-terminal ends that are not repre- 
sented in the other NFAT-family proteins. The activity of 
the NH2-terminal TAD is regulated by the adjacent NFAT 
homology region (NHR), a serine- and proline-rich region 
that contains several sequence motifs conserved within the 
NFAT family. We also  show that the conserved DBD  of 
NFAT1 contributes potently to transactivation at compos- 
ite NFAT sites, since it is capable of recruiting cooperating 
transcription factors even when expressed independently of 
the other regions ofNFAT1. Our results suggest that NFAT- 
dependent transactivation involves a  common mechanism 
mediated by the conserved DBD, as well as unique mecha- 
nisms involving the nonconserved TADs. 
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Transfections.  Jurkat cells were transfected  with 2-5 ~g of ex- 
pression  and reporter plasmids,  subdivided equally  into identical 
cultures,  incubated  for  18-24  h  at  37~  and  then  stimulated 
overnight with  1 p~M ionomycin, 10 nM PMA, or both in the 
absence or presence of 1 p~M CsA (added 30 min before the stim- 
uli). Cells were harvested  18-24 h later, and cell extracts were as- 
sayed  for chloramphenicol acetyltransferase  (CAT)  or luciferase 
activity  as described  (8). When the percent conversion of CAT 
assay was  either very high or very low,  the assay was  repeated 
with an adjusted  amount of cell lysate  to ensure  a linear range. 
Transfection efl~ciencies were determined by measuring human 
growth hormone (hGH)  expression  from a cotransfected RSV- 
hGH  plasmid  (0.5  p~g), and  protein  concentration  was  deter- 
mined by Bradford assay (Bio-Rad Laboratories,  Hercules, CA). 
GAL4 Plasmids.  GAL4-NFAT1(1-415)  was  constructed  by 
replacing  the  E2F  fragment  of GAL4-E2F  (28) between  the 
BamHI  and XbaI sites with  the  1,264-bp  fragment  of human 
NFAT1 cDNA (8), from the BssHlI site to the EcoRl site in the 
polylinker  ofpBluescript. It encodes amino acids 1-415 of NFAT1 
in frame with the GAL4 DBD (amino acids 1-147).  The GAL4- 
NFAT1(57-415), GAL4-NFATl(145-415), GAL4-NFAT1(259- 
415),  GAL4-NFAT1ASP1,  GAL4-NFAT1ASP2,  and  GAL4- 
N FAT  1ASS plasmids were made by excising appropriate restriction 
fragments from GAL4-NFAT1(1-415) and religating the plasmids. 
The COOH-terminally deleted plasmids, GAL4-NFAT1 (1-293), 
GAL4-NFATl(1-230), and GAL4-NFAT1(1-171) were made by 
replacing the BamHI-XbaI E2F fragment from GAL4-E2F with 
the appropriate restriction fragments of NFAT1. The chimeras en- 
coded by GAL4-NFATl(1-415), GAL4-NFAT1(1-293), GAL4- 
NFAT1(1-230),  GAL4-NFAT1(1-171),  GAL4-NFATIASP1, 
GAL4-NFAT1ASP2, and GAL4-NFAT1ASS have  a linker  with 
the  sequence  PEFPAGDR.IRA between  the  GAL4  DBD  and 
NFAT1 sequences. GAL4-NFATl(57-415) has a linker of  PEFPA, 
and the other NH2-terminal deletions  have a linker of PEFP. Ex- 
cept for GAL4-NFATl(1-293), GAL4-NFAT1(1-230), and GAL4- 
NFATl(1-171),  all  other constructs have  an  extra  sequence  of 
PRAEF before the stop codon. GAL4-NFAT1(727-927) was con- 
structed by replacing the NFAT1(1-415) fragment between the 
SmaI and Xbal sites in GAL4-hNFAT1(1-415) with the NcoI- 
HindlII fragment from pLGP-mNFAT1-C (8). It has a linker of 
PEFP between the GAL4 DBD and the routine NFAT1 sequence. 
GAL4-BB-E2F was  constructed  by  replacing  the  BamHI-Xbal 
fragment  of GAL4-NFAT1(57-415) with  the  XmaI-XbaI frag- 
ment of  E2F of GAL4-E2F. It has a linker of  PGI between NFAT1 
(amino acids 57-318) and E2F. The GAL4-E2F, RSV-GAL4DBD, 
RSV-CAT,  and  the  reporter  CAT  plasmid  with  three  GAL4 
DNA-binding sites (28) were gifts from Dr. Erik K.  Flemington 
(Dana-Farber Cancer Institute,  Boston, MA). 
NFA T1 Expression Plasmids.  The pEFTAG, pLGP-mNFAT1-C, 
and pEFTAG-mNFAT1-C expression  plasmids  have  been  de- 
scribed  (8). The pEFTAG-NFATl(1-415) plasmid was made by 
subcloning the  XmaI-XbaI fragment  of GAL4-NFAT1(1-415) 
into pEFTAG between the Not1 and XbaI sites. The pEFTAG- 
NFATIAN plasmid, which encodes amino acids 399-927 ofmu- 
fine NFAT1-C, was  constructed by subcloning the XhoI-XbaI 
fragment of pEFTAG-mNFAT1-C into pEFTAG between the 
Not1 and XbaI sites. The pEFTAG-NFATIDBD and pEFTAG- 
NFAT1DBDn expression plasmids, which encode amino acids 398- 
694 and 398-584 ofmurine NFATI, respectively, were constructed 
by subcloning the KpnI-BlpI fragment of NFATpXS(1-297) and 
NFATpXS(1-187) (22) into the NotI site ofpEFTAG. 
Reporter Plasmids.  The  pBLCAT5/NFAT3X  reporter  plas- 
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mid has been described  (8). The pBLCAT5/NFAT(M3)3X and 
pBLCAT5/NFAT(M4)3X reporter plasmids  were  made by re- 
placing the trimer of NFAT sites in pBLCAT5/NFAT3X with 
trimers  of NFAT(M3)  and  NFAT(M4)  (22),  respectively.  The 
NFAT3X-Luc and 5'IL2-Luc plasmids were kind gifts from Dr. 
David McKean (Mayo Clinic,  Rochester, MN). 
Results  and Discussion 
We assessed  the intrinsic  transactivation potential  of the 
NH 2- and COOH-terminal regions of NFAT1, that flank 
the centrally located DBD, by testing chimeric proteins in 
which  amino  acids  1-415  and  727-927  of NFAT1  were 
fused to the COOH  terminus of the heterologous DBD of 
GAL4. Both  regions  have  features  resembling  TADs:  the 
NH2-terminal region is acidic and proline rich, whereas the 
COOH-terminal  region is glutamine  and proline rich  (8). 
When  expressed  in Jurkat  T  cells,  both chimeric proteins 
were capable of transactivation,  provided that the reporter 
plasmid contained GAL4 binding sites  (Fig.  1 A, compare 
lane  2  with  lane  3  and  lane  4  with  lane  5).  The  GAL4 
DBD alone was inactive (lane  1). The difference in the ac- 
tivities  of GAL4-NFAT  1 (  1-415)  and  GAL4-NFAT  1 (727- 
927)  may be  a  consequence  of differences  in  the  level  of 
expression of the two GAL4 fusion proteins, or may reflect 
an intrinsic difference in their ability to transactivate in this 
context. 
When  cells  expressing  the  GAL4-NFATI(1-415)  chi- 
meric protein were stimulated with the calcium ionophore, 
ionomycin,  GAL4-dependent  transactivation  was  repro- 
ducibly  enhanced  (Fig.  1  B,  lanes  1 and  2;  2.0  +  0.4- 
fold,  n  =  8).  Stimulation  with  PMA alone  had  no  effect 
(lane 3; 0.8  +  0.1-fold, n  =  3), and stimulation with PMA 
plus ionomycin did not increase the level of CAT activity 
over that  observed with  ionomycin alone  (lane  4;  2.5  - 
0.9-fold,  n  =  3).  Notably,  CsA  completely  blocked  the 
ionomycin-induced increase  in CAT activity mediated by 
the GAL4-NFAT1(1-415) chimeric protein (Fig. 1 B; lanes 
5-8).  CsA did  not block the  basal level  of transactivation 
mediated by this protein in unstimulated Jurkat cells,  indi- 
caring that CsA does not suppress the transcriptional func- 
tion of the  chimera per se.  Transactivation  by the  GAL4- 
NFAT1(727-927)  chimeric  protein  was  not  affected  by 
ionomycin, PMA, or CsA (data not shown), indicating that 
although both the  NH2- and  COOH-terminal  regions  of 
NFAT1 possessed transactivating function, only the activity 
of the NH2-terminal region of NFAT1 was capable of be- 
ing  regulated  in  a  calcium-  and  calcineurin-dependent 
fashion.  The lack of effect of PMA on the  transactivation 
activities of these chimeras suggests that the intrinsic  trans- 
activation  activity  of NFAT1  is  not  regulated  by  PMA- 
stimulated signaling pathways. 
The (1-415) region of NFAT1 contains a unique region 
(amino acids 1-~100) not represented in the other NFAT- 
family  proteins,  as  well  as  an  adjacent  ~300-amino  acid 
NHR  (amino  acids  ~100--~380)  that  shows  a  moderate 
level  of sequence  conservation  within  the  NFAT  family 
Mechanisms of Transactivation by Nuclear Factor of  Activated T Cells Figure  1.  The transactivation and regulatory domains of NFAT1.  (A) NFAT1  has two independent transactivation domains. Jurkat ceils were trans- 
fected with 5 ~g oftLSV-GAL4DBD (lane 1), GAL4-NFAT1(1-415)  (lanes 2 and 3), or GAL4-NFAT1(727-927)  (lanes 4 and 5) together with 5 la.g of 
reporter plasmid of  GAL4-CAT (lanes  1, 2, and 4) or BG-CAT (lanes 3 and 5) and assayed for CAT activity 2 d later, as described in Materials and Meth- 
ods. (B) The transactivation activity of the GAL4-hNFAT1(1-415)  chimera protein is induced by ionomycin stimulation and is sensitive to CsA. Jurkat 
cells were transfected with 5 I~g of GAL4-hNFATI(1-415) and 5 ~g ofGAL4-CAT plasmids and cultured in eight aliquots. Cells were left unstimulated 
(lanes  1 and 5), or stimulated overnight with 1 I~M ionomycin (lanes 2 and 6), 10 nM PMA (lanes 3 and 7), or both (lanes 4 and 8), in the absence (lanes 
I-4) or presence (lanes 5-8) of I  ~M CsA. Shown is a CAT assay representative of  three independent experiments. (C) Relative transactivation activity 
of GAL4 fusion proteins with various NFAT1  NH2-terminal fragments. The GAL4 fusion proteins were expressed in Jurkat cells without (-) or with 
(+)  ionomycin (iono)  stimulation. Transfection efficiencies were normalized by measuring hGH expression from a cotransfected R.SV-hGH plasmid. 
Relative CAT activities (mean +  SD, n ~  3) shown are CAT activities normalized to that ofunstimulated cells transfected with GAL4-hNFAT1(1-415). 
Fold induction is shown where there is significant difference between CAT activities of unstimulated and ionomycin stimulated cells (P ~0.02). (8).  Detailed inspection  of the NHR  reveals the presence 
of several strongly conserved sequence motifs (8), including 
three  repeats  of the  SP  motifs  (6)  (consensus  sequence, 
SPxxSPxxSPxxxxx[D/E][D/E]).  To  localize  the  regions 
within  the  GAL4-NFAT1(1-415)  protein  required  for 
transactivation  and  regulation  by  ionomycin,  we  tested 
GAL4 chimeric proteins containing NH  2- or COOH-ter- 
minally deleted derivatives of the NFATl(1-415) fragment 
(Fig.  1  C).  These proteins were  expressed in Jurkat  cells 
with the GAL4-CAT reporter plasmid. Deletion of as few 
as 57 residues from the NH2 terminus of NFAT1 abolished 
transactivation (Fig.  1 C, row 3), and further NH2-terminal 
deletions did not restore function  (rows  4 and 5).  In con- 
trast,  chimeric proteins containing  deletions  of up to  185 
residues  from the  COOH  terminus  of the  1-415  region 
(Fig.  1 C, rows 6-10)  retained the ability to mediate trans- 
activation.  The low basal activities of proteins  containing 
the NH2-terminal half of the  NHP,  (Fig.  1  C,  rows  6-8) 
were likely due to their low level of expression, since in- 
creasing the amount ofplasmid DNA in transfections led to 
higher basal activities (data not shown); however their trans- 
activation activities were clearly augmented in ionomycin- 
stimulated cells  (row 6-8). Deletions of most of the NHR. 
(Fig.  1 C, rows 9 and  10),  or the NH2-terminal half of the 
NHP, (row  11),  resulted in high basal activities that were 
not further increased by stimulation with ionomycin, even 
when the amount ofplasmid DNA used in the transfection 
was  titrated  to  yield  a  lower basal level  of CAT  activity 
(data not shown). 
These results indicated that the NH2-terminal region of 
NFAT1 contains a strong TAD encoded within amino acids 
1-144.  However, the activity of this TAD is fully revealed 
only in the absence of amino acids 145-387, which consti- 
tute essentially all of the NHR. In the presence of the NHP,, 
moreover, the activity of the NH2-terminal TAD of NFAT1 
was regulated in a calcium/calcineurin-dependent manner. 
Indeed, we found that the NH1L was capable of conferring 
a small degree ofionomycin responsiveness on an unrelated 
protein, since transactivation by a chimeric protein (GAL4- 
BB-E2F),  in which  amino acids 57-318  of NFAT1  were 
introduced  between  the  GAL4 DBD  and  the  E2F  TAD, 
was significantly stimulated by ionomycin treatment of  Jur- 
kat  cells  (1.65  +  0.1-fold  induction,  n  =  6,  P  <0.001). 
CsA  pretreatment  reproducibly  blocked  the  ionomycin- 
mediated stimulation (1.02  +  0.32-fold induction,  n  =  6), 
but  did  not  affect  the  basal  level  of transactivation.  The 
level of transactivation by the  parent  GAL4-E2F  chimera 
was unaffected by ionomycin stimulation  (0.96  -+-+ 0.2-fold 
induction,  n =  3). 
We compared the transactivation functions of full-length 
NFAT1  with  those  of  NFAT1(399-927)  (here  termed 
NFATIAN), which lacks the NH2-terminal TAD and NHR. 
Expression of either protein in Jurkat T  cells resulted in in- 
creased  basal  transactivation  of a  CAT  reporter  plasmid 
containing three copies of the NFAT site of the routine IL-2 
promoter. As expected, further induction  of CAT activity 
by  full-length  recombinant  NFAT1  required  stimulation 
with both ionomycin and PMA, and was completely inhib- 
ited  by pretreatment  with  CsA  (Fig.  2,  left). In  contrast, 
transactivation  by  NFAT1AN  was  stimulated  by  PMA 
alone  and  was  not  inhibited  by  pretreatment  with  CsA 
(Fig. 2, right). 
We  have previously  shown  that  full-length  NFAT1  is 
cytoplasmic in resting T  cells and translocates into the nu- 
cleus upon ionomycin stimulation (8), whereas NFAT1AN 
is diffusely distributed throughout the nucleus and the cy- 
toplasm in both resting and stimulated cells  (29).  Thus, the 
results  shown  in  Fig.  2  indicate  that  nuclearly  localized 
NFAT1 and NFAT1AN require PMA for optimal transac- 
tivation, whereas ionomycin is required only for transloca- 
tion  of full-length  NFAT1  into  the  nucleus.  Given  that 
PMA does not stimulate the activity of the intrinsic TADs 
of NFAT1  (see  above),  we  postulated  that  the  PMA  re- 
quirement for transactivation most likely reflected the re- 
quirement  for cooperation  of NFAT1  with  PMA-stimu- 
lated transcription factors such as Fos andJun (1). 
To evaluate the contribution of cooperating nuclear pro- 
teins to NFATl-dependent transcription, we tested whether 
the  DBD  of NFAT1  (which  is  sufficient for cooperation 
with Fos and Jun proteins; 22)  could independently medi- 
ate transactivation. Expression of NFAT1DBD  (amino ac- 
ids 398-694 of murine NFAT1) caused transactivation of a 
hiciferase reporter plasmid containing three tandem NFAT 
sites  (NFAT3X-Luc)  in  unstimulated Jurkat  T  cells,  and 
stimulation  with  PMA  plus  ionomycin  greatly  increased 
the  level  of transactivation  (Fig.  3  A,  left). This  effect  is 
probably not  due  to  an  intrinsic  transactivation  function 
possessed by the DBD, since a longer fragment of NFAT1 
containing the NFAT1DBD does not show transactivation 
activity in vitro (4).  The effect is striking because isolated 
DNA-binding fragments of other transcription factors usu- 
ally inhibit transactivation when overexpressed, most likely 
by competing for endogenous dimerization partners and/or 
blocking the relevant sites on DNA (30,  31). 
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Figure  2.  Transactivation  by fuR-length NFAT1 and a fragment lack- 
ing the NH2-terminal  domain. Jurkat cells were transfected with 5 ~g of 
the NFAT1 (left) or NFAT1AN (right) expression plasmids and 1 p~g of 
the pBLCATS/NFAT3X reporter plasmid, and treated 1 d later with sol- 
vent (blank bars), ionomycin (striped bars), PMA (stippled bars), or ionomy- 
cin plus PMA (solid bars) in the absence (-) or presence (+) of CsA. CAT 
activity was assayed 2 d after transfection. The fold induction (mean -+ 
SD, n = 3) of CAT activity  relative to unstimulated cells is normalized for 
hGH expression. 
144  Mechanisms  of Transactivation by Nuclear Factor of Activated T Cells Figure  3.  The DBD of NFAT1  causes transcription from NFAT sites 
and the IL-2 promoter.  (A) Jurkat  cells were  transfected with  10  ~g of 
pEFTAG  (endog),  pEFTAGNFAT1-C  (FL),  pEFTAGNFAT1DBD 
(DBD),  or  pEFTAGNFAT1DBDn  (DBDn)  together  with  1  vtg  of 
NFAT-Luc (NFAT,  left) or 2  Vtg of 5'IL2-Luc (IL-2,  right) reporter plas- 
raids. Luciferase activity (in light units) was assayed as described in Mate- 
rials and Methods. (B)Jnrkat cells were transfected with 5  vtg of the indi- 
cated  expression  plasmids  and  1  vg  of pBLCAT5/NFAT3X  (WT), 
pBLCAT5/NFAT(M3)3X  (M3),  or  pBLCAT5/NFAT(M4)3X  (M4). 
Cells were left unstimulated (Unstim) or were stimulated with PMA and 
ionomycin (P +  /)  1 d after transfection. CAT activity was assayed 2 d af- 
ter transfection. The data shown are representative of at least three inde- 
pendent experiments. 
NFAT1DBD contains the region corresponding to both 
the NH2-temfinal specificity subdomain and the COOH-ter- 
minal dimerization domain of p50 NF-KB (32,  33). How- 
ever the smallest fragment of  NFAT1 capable of  DNA bind- 
ing and cooperative interaction with Fos andJun is a shorter 
187-amino acid fragment (NFATIDBDn, amino acids 398- 
584 of murine NFAT1) that corresponds to the NH2-ter- 
minal specificity subdomain of p50 NF-r,.B (32, 33). Strik- 
ingly, NFATIDBDn was also able to mediate the inducible 
transcription of NFAT3X-Luc in Jurkat T  cells  (Fig.  3 A, 
left). Moreover, both NFATIDBD and NFAT1DBDn in- 
creased the transcription of a luciferase reporter gene con- 
trolled by the IL-2 promoter (Fig.  3  A,  right).  In this case, 
the increased transcription was  apparent in stimulated but 
not  in  unstimulated Jurkat  T  cells,  presumably  because 
other inducible transcription factors such as NF-KB are re- 
quired for IL-2 promoter induction (3). 
The binding of NFAT1DBD and NFATIDBDn to the 
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composite NFAT site of the IL-2 promoter is greatly stabi- 
lized in the presence ofFos andJun (20). To test whether the 
transcriptional activation observed to be mediated by these 
fragments was due to AP-1 proteins recruited to the com- 
posite site, we used CAT reporter plasmids  containing mu- 
tated NFAT sites.  The M3 mutation of the NFAT site of 
the IL-2 promoter abrogates the binding of NFAT proteins 
and  their recruitment of AP-1  proteins,  whereas  the  M4 
mutation permits the binding of NFAT proteins but pre- 
vents  the formation of the  NFAT-Fos-Jun  complex (22, 
34). Both the M3 and M4 mutations severely compromised 
transactivation by NFATIDBD  and NFAT1DBDn  (Fig. 
3  B). Western analysis of the epitope-tagged NFATIDBD 
confirmed that it was expressed equivalently in each trans- 
fection (data not shown). These results indicated that trans- 
activation  by  NFATIDBD  and  NFATIDBDn  required 
DNA binding by the NFAT1 fragments and recruitment of 
AP-1 proteins or other cooperating transcription factors to 
the adjacent AP-1  site,  and was unlikely to involve other 
mechanisms such as squelching or titrating a repressor. 
Taken together, these results indicate that transactivation 
by NFAT-family proteins  is  regulated  at  multiple  levels. 
The strongly conserved DBDs operate even in the absence 
of intrinsic TADs to mediate transcription via cooperating 
factors  recruited  to  composite  sites.  The  minimal  187- 
amino acid DBD suffices for this effect, emphasizing the re- 
markable specialization of NFAT-family proteins for coop- 
erative interactions  on  DNA.  The  DBDs  of GATA  and 
MyoD1 are sufficient to induce cell differentiation (35, 36), 
suggesting that the use of DBDs of transcription factors as 
docking sites for recruiting other transactivating factors may 
be  a  general  mechanism  of transactivation.  NFAT1  also 
contains two intrinsic TADs that are not conserved within 
the NFAT family: indeed, the region corresponding to the 
COOH-terminal  TAD  of NFAT1  is  missing  in  NFATc 
and in the shorter isoforms of NFAT4  (5-9).  Finally, the 
conserved NHR appears to repress the activity of  the NH2- 
terminal TAD, since its removal greatly enhances transacti- 
vation mediated by the unique NH2-terminal region. 
Our  results  are  consistent with  the  hypothesis that  the 
NHR  of NFAT1  controls  the  subcellular  localization  of 
this protein, which is known to be regulated by a calcium- 
and calcineurin-dependent pathway (10).  Removal of the 
NHR or the entire NH2-terminal region from NFAT1 ab- 
rogates its  regulated subcellular localization in resting and 
stimulated T  cells (29),  and transactivation by the truncated 
protein NFATIAN is no longer sensitive to ionomycin or 
CsA.  Despite the presence of a strong nuclear localization 
signal  in the GAL4 DBD,  GAL4 chimeras containing the 
NHR  also  show  significant  responsiveness  to  ionomycin 
and CsA.  One hypothesis is that the presence of the NHR 
alters  the nuclear-to-cytoplasmic ratio of these GAL4 chi- 
meric proteins in a  calcineurin-dependent manner.  Alter- 
natively, calcineurin may regulate the ability of the NHR 
to mask the transactivation properties of the strong NH2- 
terminal TAD ofNFAT1. In either case, the NHR is likely 
to be a major target for calcineurin within NFAT1, and in 
fact we have shown that fragments containing the NHRs of both NFAT1 and NFATc bind calcineurin directly (29, 
37).  The  conserved  sequences  of the  NHRs  of NFAT- 
family proteins  suggest  that  NHR  may contribute  to  the 
CsA-sensitive  response  to  ionomycin  stimulation  of  all 
NFAT-family  members,  and  the  variation  in  NH1Ls  of 
NFAT-family proteins could account for their different be- 
havior in resting cells. 
Although there is no clearcut conservation of sequence, 
the NH/-terminal ,"~100 residues of NFAT1, NFAT3, and 
NFAT4 are each rich in acidic residues  and proline  (5-8), 
and contain acid hydrophobic patches characteristic of acidic 
TADs (8,  38, 39).  In contrast, the NH2-terminal region of 
NFATc (which is also capable of transactivation;  Luo, C., 
unpublished data) is proline rich but not acidic. Thus trans- 
activation by the  different  NFAT-family proteins  may be 
mediated  by  distinct  interactions  of the  different  TADs 
with  coactivators,  TATA,  binding  protein-associated  fac- 
tors  (TAFs),  and other components of the basal transcrip- 
tion machinery  (40).  In conjunction with the  distinct  site 
preferences of NFAT-family proteins (7, 9) and the diverse 
sequences  and  arrangements  of NFAT  sites  in  inducible 
promoter/enhancer  regions  (1),  such interactions  may de- 
termine the cell-specific expression ofcytokine genes. 
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